Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

HCV medications' side effects can now be replicated and observed in Petri dishes and test tubes

The adverse side effects of certain hepatitis C medications can now be replicated and observed in Petri dishes and test tubes, thanks to a research team led by Craig Cameron, the Paul Berg Professor of Biochemistry and Molecular Biology at Penn State University.

17 Nov 2012

HUCPVC cell therapy more effective in restoring heart function after myocardial infarction

A study published this month by researchers at the University of Toronto and Toronto's Princess Margaret Hospital has shown that cells derived from the umbilical cord, "Human Umbilical Cord PeriVascular Cells" (HUCPVCs), are more effective in restoring heart function after an acute myocardial infarction (in common parlance, a heart attack) in a pre-clinical model than a similar cell population derived from bone marrow.

16 Nov 2012

Peak interest in health issues comes at about age 51 for baby boomers

For baby boomers, the peak interest in health issues comes at about age 51, with a second peak coming near age 65, according to a new study.

16 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

BMI may not be best measure for estimation of cancer risk

A study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that body mass index (BMI)-the most commonly used weight-for-height formula for estimating fatness-may not be the best measure for estimating disease risk, and particularly the risk of certain types of cancer. The study was published today in the online edition of the American Journal of Epidemiology.

8 Nov 2012

Liver transplant waitlist mortality not simply due to lack of donor organs: Study

The majority of patients on the liver transplant waitlist who died received offers of high-quality donated livers that were declined prior to their death, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. Therefore, efforts other than simply increasing the availability of donated livers or the number of offers are needed to substantially reduce the deaths among those waiting for a transplant.

7 Nov 2012

NY-Presbyterian/CUMC wins two Transplant Program Awards from HSS

NewYork-Presbyterian Hospital/Columbia University Medical Center was named a recipient of two Transplant Program Awards from the U.S. Department of Health and Human Services (HSS) for its outstanding performance on liver and lung transplantation.

3 Nov 2012

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.

3 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

Study shows reduced risk of liver-related mortality in African American women with HIV/HCV

A new study shows that African American women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are less likely to die from liver disease than Caucasian or Hispanic women. Findings in the November issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, indicate that lower liver-related mortality in African American women was independent of other causes of death.

1 Nov 2012

Nitisinone treatment effectively prevents tyrosinemia in children

A consortium of Quebec researchers coordinated by the Medical Genetics Service of the Sainte-Justine UHC has just published the findings of a 25-year study on the treatment of tyrosinemia, a life-threatening liver disease of genetic origin, which is screened at birth in the province of Quebec, where it is much more frequent than anywhere else in the world.

1 Nov 2012

African American women coinfected with HIV and HCV less likely to die from liver disease than Caucasian or Hispanic women

31 Oct 2012

BioCryst announces withdrawal of BCX5191 IND following discussion with FDA

BioCryst Pharmaceuticals, Inc. announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).

31 Oct 2012

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump system in patients with ascites caused by cancer (malignant ascites).

30 Oct 2012

Oxidative stress occurs in genetic models of alpha-1-antitrypsin deficiency

A team of researchers under the direction of Dr. Jeffrey Teckman in the Department of Pediatrics at St. Louis University, have demonstrated that oxidative stress occurs in a genetic model of alpha-1-antitrypsin deficiency.

30 Oct 2012

Transplant wait-list deaths not just due to organ availability: Study

Most liver transplant candidates who died or were removed from the transplant list actually received one or more liver donation offers, according to a recent UCSF study.

23 Oct 2012

SLU medical students to raise awareness about teen suicide among tech savvy millennials

Two Saint Louis University medical students are taking the multimedia route to raise awareness about teen suicide among tech savvy millennials.

23 Oct 2012

Einstein College receives $3M grant to establish Glenn Center for the Biology of Human Aging Research

Albert Einstein College of Medicine of Yeshiva University has received a $3 million grant from the Glenn Foundation for Medical Research to establish the Paul F. Glenn Center for the Biology of Human Aging Research. The grant will fund research to translate recent laboratory and animal discoveries into therapies to slow human aging.

15 Oct 2012

Database of drug-induced liver injury now available from NIH

A free source of evidence-based information for health care professionals and for researchers studying liver injury associated with prescription and over-the-counter drugs, herbals, and dietary supplements is now available from the National Institutes of Health. Researchers and health care professionals can use the LiverTox database to identify basic and clinical research questions to be answered and to chart optimal ways to diagnose and control drug-induced liver injury.